RPTX241018C5000
- 0.05
- 0.000.00%
Repare Therapeutics Newsroom
LifeSci Capital Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $8
Piper Sandler Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $25
Stifel Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $9
Stifel Nicolaus Keeps Their Buy Rating on Repare Therapeutics (RPTX)
Morgan Stanley Maintains Repare Therapeutics(RPTX.US) With Hold Rating, Maintains Target Price $8
Hold Rating on Repare Therapeutics Amidst Early Promising Clinical Results and Safety Concerns
Repare Therapeutics Analyst Ratings
H.C. Wainwright Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $10
Buy Rating Reaffirmed for Repare Therapeutics on Strong Clinical Data and Market Potential
Piper Sandler Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $25
Bloom Burton Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $15
Morgan Stanley Maintains Repare Therapeutics(RPTX.US) With Hold Rating, Maintains Target Price $8
Repare Therapeutics Analyst Ratings
H.C. Wainwright Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $10
LifeSci Capital Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $8
Buy Rating on Repare Therapeutics Amidst Promising Clinical Trials and Strong Financials
Analysts' Opinions Are Mixed on These Healthcare Stocks: Walgreens Boots Alliance (WBA), 2seventy Bio (TSVT) and Repare Therapeutics (RPTX)
Stifel Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $9
LifeSci Capital Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $8
LifeSci Capital Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Cuts Target Price to $8